Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction: REVEAL: A Randomized Controlled Trial.

The article discusses a study of the safety and efficacy of a single intravenous bolus of epoetin alfa in patients with ST-segment elevation myocardial infarction (STEMI) in the U.S. conducted from October 2006 to February 2010. The risk for developing infarct expansion and left ventricular (LV) remodeling are facing patients who survive STEMI. Vital signs, hemoglobin level, reticulocyte count and clinical events were some of the factors considered as safety end points. Results show a lack of association between infarct size and time from study drug administration to first cardiac magnetic resonance (CMR). Also noted is the higher incidence of adverse events in participants who received epoetin alfa.